| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
254,921 |
421,551 |
1,262,027 |
1,480,093 |
| Total Sell Value |
$16,747,919 |
$26,516,522 |
$74,515,877 |
$82,888,946 |
| Total People Sold |
8 |
9 |
12 |
12 |
| Total Sell Transactions |
23 |
40 |
87 |
90 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Holubow Fred |
Director |
– • – |
2015-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
800 |
15,533 |
|
- |
|
| Marken James G. |
Vice President, Operations |
• – – |
2015-03-19 |
4 |
S |
$66.50 |
$997,500 |
D/D |
(15,000) |
31,568 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2015-03-12 |
4 |
S |
$63.00 |
$4,725,000 |
D/D |
(75,000) |
114,164 |
|
- |
|
| Raynor Daniel |
Director |
– • – |
2015-03-12 |
4 |
S |
$63.00 |
$12,600,000 |
I/I |
(200,000) |
324,182 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2015-03-12 |
4 |
S |
$63.00 |
$18,900,000 |
D/D |
(300,000) |
2,350,559 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2015-03-12 |
4 |
S |
$63.00 |
$13,230,000 |
I/I |
(210,000) |
5,870 |
|
- |
|
| Arnold Charlotte C. |
Vice President and CFO |
• – – |
2015-03-12 |
4 |
S |
$63.00 |
$2,835,000 |
D/D |
(45,000) |
21,385 |
|
- |
|
| Mangano Ross J |
Director |
– • – |
2014-09-15 |
4 |
B |
$27.49 |
$82,477 |
D/D |
3,000 |
26,914 |
2.39 |
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2014-09-09 |
4 |
B |
$26.50 |
$26,500 |
D/D |
1,000 |
189,162 |
2.81 |
- |
|
| Marken James G. |
Vice President, Operations |
• – – |
2014-06-18 |
4 |
S |
$34.28 |
$171,400 |
D/D |
(5,000) |
46,568 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
12,800 |
188,162 |
|
- |
|
| Arnold Charlotte C. |
VP and CFO |
• – – |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
66,385 |
|
- |
|
| Marken James G. |
Vice President, Operations |
• – – |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
51,568 |
|
- |
|
| Schrepfer Robert W |
VP Bus Dev & Con Mfg |
• – – |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Jamnick Robert J. |
VP, Quality & Product Develop. |
• – – |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
48,118 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2014-05-08 |
4 |
S |
$30.02 |
$41,455 |
I/I |
(1,381) |
21,634 |
|
- |
|
| Mangano Ross J |
Director |
– • – |
2014-05-07 |
4 |
B |
$30.38 |
$60,760 |
D/D |
2,000 |
23,914 |
2.39 |
- |
|
| Marshbanks Tracy |
Director |
– • – |
2014-03-21 |
4 |
S |
$31.06 |
$174,467 |
I/I |
(5,617) |
8,111 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2014-03-20 |
4 |
S |
$31.54 |
$509,384 |
I/I |
(16,150) |
8,173 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2014-03-20 |
4 |
S |
$31.76 |
$317,600 |
D/D |
(10,000) |
2,650,559 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2014-03-19 |
4 |
S |
$32.38 |
$354,390 |
D/D |
(10,922) |
2,660,559 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2014-03-19 |
4 |
S |
$32.98 |
$140,025 |
I/I |
(4,246) |
8,350 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2014-03-18 |
4 |
S |
$33.83 |
$714,143 |
I/I |
(21,112) |
8,397 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2014-03-18 |
4 |
S |
$33.83 |
$694,936 |
D/D |
(20,542) |
2,671,481 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2014-03-17 |
4 |
S |
$34.75 |
$359,280 |
D/D |
(10,339) |
2,692,023 |
|
- |
|
722 Records found
|
|
Page 17 of 29 |
|
|
0.14 (0.21%) 
